18F-FDG PET/CT evaluation of Ceritinib therapy in metastatic ALK-positive non-small cell lung cancer - Archive ouverte HAL Access content directly
Journal Articles Clinical Nuclear Medicine Year : 2016

18F-FDG PET/CT evaluation of Ceritinib therapy in metastatic ALK-positive non-small cell lung cancer

, (1, 2, 3) , , , (1, 2, 3)
1
2
3

Abstract

Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancers (NSCLC) account for 3% to 7% of all NSCLC and require a standard treatment by crizotinib. However, crizotinib resistance is frequent within the first 12 months of treatment. Ceritinib is a novel tyrosine kinase inhibitor of ALK recently introduced in France for metastatic or locally advanced crizotinib-resistant ALK NSCLC. We report the first use of ceritinib in our institution with a spectacular tumoral response after only 3 months of treatment. This case demonstrates the major role of F-FDG PET/CT for monitoring the effectiveness of this new treatment.
Not file

Dates and versions

hal-01822370 , version 1 (25-06-2018)

Identifiers

Cite

Sébastien Dejust, David Morland, Fabre Guillaume, Alain Prévost, Dimitri Papathanassiou. 18F-FDG PET/CT evaluation of Ceritinib therapy in metastatic ALK-positive non-small cell lung cancer. Clinical Nuclear Medicine, 2016, 41 (11), pp.879-880. ⟨10.1097/RLU.0000000000001361⟩. ⟨hal-01822370⟩

Collections

URCA CRESTIC
36 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More